JCJaehyeong Cho

Jaehyeong Cho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jaehyeong Cho has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MENTOR: An Evidence-Informed Large Language Model-Based Multi-Agent System for Efficient Selection of Institution-Specific Negative Control Outcomes

    by Taeseok Yang, Junhyuk Chang, Yeonghyeon Kim, Jaehyeong Cho, Kyungseon Choi, Minkook Son, Chungsoo Kim

    Objective: Negative control outcomes (NCOs) help detect and correct systematic error in observational studies, yet their selection remains largely manual. The Common Evidence Model (CEM) can generate candidate lists, but researchers must still screen them for plausibility as true nulls and for sufficient observation in each institution’s data. We developed and evaluated MENTOR (Multi-agent Evidence-informed Negative conTrol Outcome selection with Reasoning), a multi-agent system of large language models (LLMs) that combines CEM evidence with LLM reasoning to select institution-specific NCOs. Methods: Four LLM agents operate on an institution’s Observational Medical Outcomes Partnership common data model. A Curator summarizes drug labels, a Suggester assesses locally frequent candidates with CEM evidence and a first-pass LLM judgment, an Adjudicator resolves their disagreements, and a Diagnostician relaxes the patient-count threshold until a target number of NCOs is met. Using Qwen3.6-27B, we evaluated 349 candidates for three drug pairs in a Korean tertiary hospital’s electronic health records (2.9 million patients) against a blinded LLM judge from a different model family, validated by three experts on 90 candidates. We compared accuracy, positive predictive value (PPV), and sensitivity with CEM-only and first-pass-LLM-only selection. Results: MENTOR proposed 243 NCOs versus 121 by CEM-only, with higher accuracy (0.83 [0.79–0.87] vs. 0.53 [0.48–0.58]), sensitivity (0.89 vs. 0.41), and PPV (0.86 vs. 0.79). Judge–expert agreement was κ=0.63. Adjudication, needed for 44.1% of candidates, added little accuracy, and only with reasoning mode. Concordant acceptances, which bypass it, contained about half of the false positives. Only 7%–9% of CEM-proposed outcomes had at least 10,000 patients at the institution. Conclusion: Combining LLM judgments with CEM evidence and local data yielded more NCOs, with higher PPV, than CEM alone. Restricting reasoning to discordant candidates kept computation time below 40% of that with reasoning in all agents. Every decision comes with its evidence and rationale for investigators’ final review.

  • Open Access

    Antidepressants and the risk of hyponatremia: A multi‐institutional cohort study using observational medical outcomes partnership—Common Data Model

    by Kyungyeon Jung, Ju Hwan Kim, Da Eun Hyeon, Jeongmoon Ji, Min Young Lee, Hayun Choi, Dong Yun Lee, Min Woo Kim, Yoonmin Jang, Seonghoon Hwang, et al.

    Aim: Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods: Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023), we identified patients diagnosed with depression who initiated antidepressants, including selective serotonin reuptake inhibitor (SSRI), serotonin–norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressants (TCA) or others (agomelatine, bupropion, mirtazapine, moclobemide and trazodone) for at least 30 days. The index date was defined as the first antidepressant prescription, and four mutually exclusive cohorts were constructed based on the antidepressant class prescribed on index date. Each cohort was compared with all other antidepressants. The primary outcome was incident hyponatremia (serum sodium <135 mmol/L) within the first 180 days. After propensity score stratification, hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression. Fixed‐effect meta‐analysis was used to pool the results from each site. Results: We identified 17 895 (42.6%) patients in SSRI, 7395 (17.6%) in SNRI, 5424 (12.9%) in TCA and 11 322 (26.9%) in other group. The risk of hyponatremia increased within 180 days after SSRI initiation (HR 1.18, 95% CI 1.01–1.38) compared with all other depressants, with a higher risk in patients aged ≥60 years (1.29, 1.06–1.57). No significant association was found for SNRIs (1.05, 0.87–1.27), TCAs (1.03, 0.84–1.26) or other (0.90, 0.77–1.06). Conclusion: Close monitoring of serum sodium levels is essential for SSRI users, especially those aged ≥60 years.


  • Open Access

    Temporal Trend of Cardiovascular Disease Burden Among Cancer Patients Between 2005 and 2022: Nationwide Population-Based Cohort Study in South Korea

    by Iksung Cho, Seonhwa Lee, Jaehyeong Cho, Hasung Kim, Jungkuk Lee, Hui-Jeong Hwang, Eun Jeong Cho, Hee Jun Kim, Seong-Mi Park, Sung-Eun Kim, et al.

    Cho I, et al. Korean Circ J. 2026 ;56:e53. https://doi.org/10.4070/kcj.2025.0171


  • Open Access

    Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study

    by Ji-Yong Jang, Seonji Kim, Jaehyeong Cho, Sung-Youn Chun, Seng Chan You, Jung-Sun Kim

    The long-term outcome of first-line moderate-intensity statin with ezetimibe combination therapy for secondary prevention after percutaneous coronary intervention in patients with acute coronary syndrome (ACS) compared to high-intensity statin monotherapy remains elusive. The objective of this study was to compare the effectiveness of moderate-intensity statin and ezetimibe combination therapy with high-intensity statin monotherapy. We conducted a nationwide, population-based, retrospective, cohort study of patients with ACS from 2013 to 2019. The patients using combination therapy were matched (1:1) to those using monotherapy. The primary outcome was a composite of myocardial infarction, stroke and all-cause mortality. We estimated the hazard ratios (HR) and 95% confidence intervals (CIs) using the Cox proportional hazards regression. After propensity score matching, 10,723 pairs were selected. Men accounted for 70% of the patients and 37% aged > 70 years. The primary endpoint occurred in 1297 patients (12.1%) in the combination group and in 1426 patients (13.3%) in the monotherapy group, and decreased risk (HR 0.85, 95% CI 0.78–0.92, P < 0.001) in the combination group. Among the patients with ACS, moderate-intensity statin with ezetimibe combination therapy was associated with decreased risk of adverse cardiovascular outcomes compared with high-intensity statin monotherapy in a nationwide population-based study representing routine clinical practice.


  • Open Access

    Incorporation of Korean Electronic Data Interchange Vocabulary into Observational Medical Outcomes Partnership Vocabulary

    by Yeonchan Seong, Seng Chan You, Anna Ostropolets, Yeunsook Rho, Jimyung Park, Jaehyeong Cho, Dmitry Dymshyts, Christian G. Reich, Yunjung Heo, Rae Woong Park

    We incorporated the Korean Electronic Data Interchange (EDI) vocabulary into Observational Medical Outcomes Partnership (OMOP) vocabulary using a semi-automated process. The goal of this study was to improve the Korean EDI as a standard medical ontology in Korea. We incorporated the EDI vocabulary into OMOP vocabulary through four main steps. First, we improved the current classification of EDI domains and separated medical services into procedures and measurements. Second, each EDI concept was assigned a unique identifier and validity dates. Third, we built a vertical hierarchy between EDI concepts, fully describing child concepts through relationships and attributes and linking them to parent terms. Finally, we added an English definition for each EDI concept. We translated the Korean definitions of EDI concepts using Google.Cloud.Translation.V3, using a client library and manual translation. We evaluated the EDI using 11 auditing criteria for controlled vocabularies. We incorporated 313,431 concepts from the EDI to the OMOP Standardized Vocabularies. For 10 of the 11 auditing criteria, EDI showed a better quality index within the OMOP vocabulary than in the original EDI vocabulary. The incorporation of the EDI vocabulary into the OMOP Standardized Vocabularies allows better standardization to facilitate network research. Our research provides a promising model for mapping Korean medical information into a global standard terminology system, although a comprehensive mapping of official vocabulary remains to be done in the future.


  • Open Access

    Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts

    by Seng Chan You, Sungjae Jung, Joel N. Swerdel, Patrick B. Ryan, Martijn J. Schuemie, Marc A. Suchard, Seongwon Lee, Jaehyeong Cho, George Hripcsak, Rae Woong Park, et al.

    2018 ESC/ESH Hypertension guideline recommends 2-drug combination as initial anti-hypertensive therapy. However, real-world evidence for effectiveness of recommended regimens remains limited. We aimed to compare the effectiveness of first-line anti-hypertensive treatment combining 2 out of the following classes: angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blocker (A), calcium channel blocker (C), and thiazide-type diuretics (D). Treatment-naïve hypertensive adults without cardiovascular disease (CVD) who initiated dual anti-hypertensive medications were identified in 5 databases from US and Korea. The patients were matched for each comparison set by large-scale propensity score matching. Primary endpoint was all-cause mortality. Myocardial infarction, heart failure, stroke, and major adverse cardiac and cerebrovascular events as a composite outcome comprised the secondary measure. A total of 987,983 patients met the eligibility criteria. After matching, 222,686, 32,344, and 38,513 patients were allocated to A+C vs. A+D, C+D vs. A+C, and C+D vs. A+D comparison, respectively. There was no significant difference in the mortality during total of 1,806,077 person-years: A+C vs. A+D (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.97-1.20; p=0.127), C+D vs. A+C (HR, 0.93; 95% CI, 0.87-1.01; p=0.067), and C+D vs. A+D (HR, 1.18; 95% CI, 0.95-1.47; p=0.104). A+C was associated with a slightly higher risk of heart failure (HR, 1.09; 95% CI, 1.01-1.18; p=0.040) and stroke (HR, 1.08; 95% CI, 1.01-1.17; p=0.040) than A+D. There was no significant difference in mortality among A+C, A+D, and C+D combination treatment in patients without previous CVD. This finding was consistent across multi-national heterogeneous cohorts in real-world practice.


  • Open Access

    Application for Epidemiological Geographic Information System: An Open-Source Spatial Analysis Tool based on the Common Data Model (Preprint)

    by Jaehyeong Cho, Seng Chan You, Seongwon Lee, DongSu Park, Bumhee Park, George Hripcsak, Rae Woong Park

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Although spatial epidemiology is widely used to evaluate geographic variations and disparities in health outcomes, constructing geographic statistical models usually requires a labor-intensive process that limits its overall utility. Objective: This study aimed to develop open-source software for scalable spatial epidemiological analysis based on standardized geocode and a health care database and to demonstrate its applicability and methodological quality across countries. Methods: We developed Application for Epidemiological Geographic Information System (AEGIS) based on a standardized geocode and common data model (CDM) for health care data. AEGIS was implemented to access the geographic distribution in the incidences and health outcomes of non–communicable and communicable diseases in South Korea and the United States, specifically, the (1) geographical distribution of incident cancers, (2) spatial heterogeneity of 5-year mortality in Korean patients with cancer, and (3) identification of an endemic area of malaria in South Korea and the United States. The results from South Korea were compared with those of previous studies to assess the reliability of AEGIS. Results: AEGIS provides two widely used spatial analysis methods for health outcome assessment: disease mapping and detection of concentrated clusters of medical conditions or outcomes. It was possible to describe the spatial distribution, assess the spatial heterogeneity, and detect the focused area of a medical condition or outcome in various databases from different countries. The AEGIS-generated spatial distribution of incident cancer in Korea was consistent with those of previous reports. AEGIS was able to detect the known endemic area of malaria in South Korea. Conclusions: As an open-source, cross-country, spatial analytics solution, AEGIS may globally expedite the assessment of differences in geographic health outcomes through the use of standardized geocode and health care databases.


  • Open Access

    Application for Epidemiological Geographic Information System: An Open-Source Spatial Analysis Tool based on the Common Data Model (Preprint)

    by Jaehyeong Cho, Seng Chan You, Seongwon Lee, DongSu Park, Bumhee Park, George Hripcsak, Rae Woong Park

    BACKGROUND Although spatial epidemiology is widely used to evaluate geographic variations and disparities in health outcomes, constructing geographic statistical models usually requires a labor-intensive process that limits its overall utility. OBJECTIVE This study aimed to develop open-source software for scalable spatial epidemiological analysis based on standardized geocode and a health care database and to demonstrate its applicability and methodological quality across countries. METHODS We developed Application for Epidemiological Geographic Information System (AEGIS) based on a standardized geocode and common data model (CDM) for health care data. AEGIS was implemented to access the geographic distribution in the incidences and health outcomes of non–communicable and communicable diseases in South Korea and the United States, specifically, the (1) geographical distribution of incident cancers, (2) spatial heterogeneity of 5-year mortality in Korean patients with cancer, and (3) identification of an endemic area of malaria in South Korea and the United States. The results from South Korea were compared with those of previous studies to assess the reliability of AEGIS. RESULTS AEGIS provides two widely used spatial analysis methods for health outcome assessment: disease mapping and detection of concentrated clusters of medical conditions or outcomes. It was possible to describe the spatial distribution, assess the spatial heterogeneity, and detect the focused area of a medical condition or outcome in various databases from different countries. The AEGIS-generated spatial distribution of incident cancer in Korea was consistent with those of previous reports. AEGIS was able to detect the known endemic area of malaria in South Korea. CONCLUSIONS As an open-source, cross-country, spatial analytics solution, AEGIS may globally expedite the assessment of differences in geographic health outcomes through the use of standardized geocode and health care databases.